Faster healing. Deeper protection. Gentle care. Clinically formulated to accelerate healing and help protect against infection across all types of chronic and complex wounds.
Zegen-X5 is our lead product candidate — a newly formulated, shelf-stable topical cream engineered to penetrate hostile wound environments, modulate the regenerative cascade, and accelerate tissue repair across the full spectrum of chronic and complex wounds.
42% faster wound closure vs. control at Day 7 in preclinical models.
Forms a protective barrier; designed for hostile wound microenvironments.
Gentle topical formulation with no significant irritation in tox studies.
Suited to fragile skin, pediatric and geriatric patients, repeat application.
From diabetic ulcers to surgical incisions, Zegen-X5 is designed as a single platform that addresses the most clinically and economically significant wound categories.
First, second & third-degree thermal injuries — accelerating re-epithelialization while reducing scarring potential.
The lead indication. 18.3M patients globally; current standards fail one in four. Our primary IND filing pursues DFUs.
Post-operative incisions and surgical-site complications — reducing dehiscence risk and accelerating recovery.
Everyday traumatic injuries — including in trauma, military and home-use settings where cold-chain therapeutics are impossible.
Decubitus ulcers in long-term care and immobile patients — a $2.8B segment with poor existing therapeutic options.
Highly recurrent, quality-of-life devastating. A $3.2B segment for Zegen-X5 expansion post-DFU.
The active pharmaceutical ingredient is only half the story. Our formulation team engineered a topical matrix that protects, permeates and persists — so the molecule arrives where it needs to act and stays there long enough to work.
Statistically significant efficacy across multiple wound models
Composition of matter through 2044+
Long-term stability validated under regulatory standard
GLP tox in progress; first-in-human study 2026
Detailed product specifications, preclinical evidence, and clinical development plan available to qualified partners under NDA.
A preclinical-stage biopharmaceutical company developing first-in-class, shelf-stable wound healing therapeutics — making advanced care accessible everywhere.
